UPDATE 1-Alexion Q4 profit beats Street
* Q4 EPS 17 cents tops Street view by 9 cents
* Revenue more than doubles to $77.4 mln
Feb 12 (Reuters) - Alexion Pharmaceuticals Inc (ALXN.O) posted better-than-expected quarterly earnings as revenue from its genetic-disorder drug Soliris more than doubled.
The pharmaceutical company derives all of its revenue from Soliris, which treats paroxysmal nocturnal hemoglobinuria (PNH). The rare genetic disorder can lead to anemia, fatigue, pain and difficulty in breathing.
The company forecast fiscal 2009 earnings of $1 to $1.05 a share, excluding stock-based compensation, on sales of $360 million to $375 million.
For the fourth quarter, the company's net income was $15.3 million, or 17 cents a share, compared with a loss of $12.3 million, or 17 cents a share, a year-ago.
Soliris sales more than doubled to $77.4 million.
Shares of the company closed at $36.88 Wednesday on Nasdaq.
For alerts, double-click [ID:nWNAB1846] (Reporting by Anand Basu in Bangalore; Editing by Vinu Pilakkott)
- Malaysia military tracked missing plane to west coast: source |
- Malaysia air probe finds scant evidence of attack: sources |
- Confrontation in Ukraine as diplomacy stalls |
- N.Korea using sophisticated means to avoid U.N. sanctions - U.N. report
- Freescale loss in Malaysia tragedy leads to travel policy questions